Scientists from the Helmholtz Zentrum München in cooperation with the University of Cincinnati, USA, have discovered that the placement of a non-permeable tube in the small intestine leads to reduced nutrient absorption and consequently to reduced obesity and enhanced glucose metabolism. These findings are published in the current issue of the British medical journal ‘Gut’.
Bariatric surgeries, such as a gastric bypass, are currently the most effective anti-obesity therapies. They also lead to a reduced insulin resistance. However, the pitfall of these surgical interventions is that they are highly invasive and often permanent procedures. An international team of scientists led by Dr. Kirk Habegger, Metabolic Disease Institute, University of Cincinnati, and Prof. Dr. Matthias Tschöp, Scientific Director of the Helmholtz Diabetes Center (HDC) at the Helmholtz Zentrum München (HMGU), Partner of the German Center for Diabetes Research (DZD), have now developed an equally efficient but less invasive surgical method, thus paving the way for the development of novel safe and efficient anti-obesity therapies.
In their study, a flexible tube, called a DES (duodenal-endoluminal sleeve), was placed in the small intestine. Tschöp, Habegger, and colleagues observed that this intervention in an animal model potently corrects obesity while improving glucose metabolism. The metabolic benefits of this novel surgical intervention seem to be mediated via reduced nutrient absorption in the intestinal lumen and reactive mucous membrane growth in the other intestinal sections, a shift which may lead to improved nutrient utilization. The intervention carries the great advantage that it is less invasive and removable at any time.
The method is consequently seen as a promising approach to treat obesity and diabetes. Further studies now aim to clarify which influence this novel surgical technique has on the complex neuroendocrine network that controls energy metabolism. The long-term goal based on such better understanding is to optimize devices to the level where they can be used successfully in humans, potentially in combination with hormone based drug therapies. (Also see press release “Enhancing weight loss: Gastric banding with hormone therapy”)
The numerous conditions associated with overweight and obesity, such as type 2 diabetes, are among the major widespread diseases in Germany. They are the focus of the research at the Helmholtz Zentrum München.
Habegger, KM et al (2013). Duodenal Nutrient Exclusion Improves Metabolic Syndrome and Stimulates Villus Hyperplasia, Gut, doi:10.1136/gutjnl-2013-304583
As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,100 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 34,000 staff members.
The German Center for Diabetes Research (DZD) brings together experts in the field of diabetes research and interlinks basic research, epidemiology and clinical applications. Members are the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrücke, Helmholtz Zentrum München – German Research Center for Environmental Health, the Paul Langerhans Institutes of the University Hospital Carl Gustav Carus in Dresden and the University of Tübingen, as well as the Gottfried Wilhelm Leibniz Association and the Helmholtz Association of German Research Centres. The objective of the DZD is to find answers to open questions in diabetes research by means of a novel, integrative research approach and to make a significant contribution to improving the prevention, diagnosis and treatment of diabetes mellitus.
The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).
Prof. Matthias Tschöp, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Institute of Diabetes and Obesity, Ingolstaedter Landstr. 1, D-85764 Neuherberg - Tel. +49 89 3187-2103
Helmholtz Zentrum München -
Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Ingolstädter Landstraße 1